BDULFBangkok Dusit Medical Services Public Company Limited
The Read
BDULF's stock remained flat after Q1 2026 earnings matched estimates and stayed flat again in Q2 2026 due to lack of directional catalysts and mixed signals on patient volume and margins.
The schedule
- Thu15Oct
Policy updates affecting public healthcare tariffs and private facility reimbursements
- Fri13Nov
Key earnings report with guidance on patient volume and cost controls
- Fri12Feb
- Fri19Feb
Annual results with growth strategy emphasis on digital health integration
- Mon10May
- Mon9Aug
Past
- Fri14Aug
Actual outcome: Bull · $0.66 at outcome
BDULF reported Q2 2026 EPS of $0.23, coming in exactly in line with consensus estimates. The stock held steady and exceeded the $0.64 bull target, driven by a reassuring mid-year assessment of international patient volumes and elective procedure recovery that satisfied market expectations.
Bangkok Dusit Medical Services releases its Q2 2026 financials, with market focus squarely on international patient volume recovery and operating margins.
- Fri15May
Actual outcome: Mixed · $0.66 at outcome
BDULF reported Q1 2026 EPS of $0.23, exactly matching consensus estimates. Because the financial results offered no major surprises to either the upside or downside, the report failed to provide a fresh directional catalyst. Consequently, amid already extreme overbought technical conditions, the stock remained completely flat as the market digested the in-line performance.